As of June 12, 2025, BioInvent International AB (BINV.ST) reports a Gross Margin of 42.37%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Comparing BioInvent International AB's Gross Margin to Peers
To better understand BioInvent International AB's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| BioInvent International AB (BINV.ST) | 42.37% |
| Nordic Nanovector ASA (NANOV.OL) | 7775.20% |
| Biophytis SA (ALBPS.PA) | 7775.20% |
| Sensorion SA (ALSEN.PA) | 7775.20% |
| XSpray Pharma AB (publ) (XSPRAY.ST) | 2539.90% |
| E-Therapeutics PLC (ETX.L) | 100.00% |
Compared to its competitors, BioInvent International AB's Gross Margin is among the lowest compared to peers, suggesting potential challenges in production costs or pricing strategy.